EGFR and non-small cell lung carcinoma: In our model, osimertinib first-line treatment for EGFR-mutated advanced NSCLC is an exciting new therapy that leads to a prolonged overall survival and an improvement in QALYs gained, but the ICER is higher than the WTP threshold of China.